by Garth Sundem | Dec 13, 2019 | Featured, Latest News
Robert C. Doebele, MD, PhD Pooled analysis of three phase 1 and 2 clinical trials published online ahead of print in the journal Lancet Oncology show that the drug entrectinib is effective and well-tolerated against advanced ROS1 and NTRK fusion-positive non-small...
by Garth Sundem | Nov 19, 2019 | Featured, Research
Cathy J. Bradley, PhD Genetically targeted drugs and immunotherapies are transforming the way we treat many forms of lung cancer. However, a University of Colorado Cancer Center study published in the Journal of the National Cancer Institute shows that while the use...
by Garth Sundem | Nov 19, 2019 | Featured, Philanthropy
Paul and Nancee Pronsati, not in Denver If Nancee Pronsati had been diagnosed with stage IV ALK-positive lung cancer a decade ago, her years of life expectancy would have been measured with fewer fingers than it takes to make a peace sign. But due to advances in...
by Taylor Abarca | Nov 1, 2019 | Featured, Latest News, Patient Care
Lung Cancer Misconceptions Lung cancer is the number one cause of cancer related death in both men and women in the United States. In fact, according to the American Cancer Society, more people die of lung cancer than of colon, breast, and prostate cancers combined. ...
by Taylor Abarca | Oct 17, 2019 | Latest News
From Lung Cancer Canada: In a special episode to commemorate the anniversary of the legalization of recreational cannabis, Dr. Paul Wheatley-Price talks to Dr. Ross Camidge, Director of Thoracic Oncology at the University of Colorado, about the myths and facts...
